Posttranslational Modification of MDM2

Molecular Cancer Research

Volumn 1, Issue 14, 2003, Pages 1017-1026

  Meek, David W ^a   Knippschild, Uwe ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CASEIN KINASE II; CELL PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ACIDITY; CELL CYCLE; CELL SURVIVAL; CELLULAR DISTRIBUTION; ENZYME ACTIVITY; GROWTH REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; STRESS; UBIQUITINATION; ZINC FINGER MOTIF;

HUMANS; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 0346455772     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994.
2. Ladanyi, M., Lewis, R., Jhanwar, S. C., Gerald, W., Huvos, A. G., and Healey, J. H. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J. Pathol., 175: 211-217, 1995.
3. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
4. Momand, J., Wu, H. H., and Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein. Gene, 242: 15-29, 2000.
5. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 362: 857-860, 1993.
6. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
7. Michael, D. and Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol., 13: 49-58, 2003.
8. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2: 405-415, 1998.
9. Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., and Livingston, D. M. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science, 300: 342-344, 2003.
10. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
11. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 17: 554-564, 1998.
12. Ito, A., Kawaguchi, Y., Lai, C. H., Kovacs, J. J., Higashimoto, Y., Appella, E., and Yao, T. P. MDM2-HDACl-mediated deacetylation of p53 is required for its degradation. EMBO J., 21: 6236-6245, 2002.
13. Iwakuma, T. and Lozano, G. Mdm2, an introduction. Mol. Cancer Res., 1: 993-1000, 2003.
14. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
15. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274: 948-953, 1996.
16. Thut, C. J., Goodrich, J. A., and Tjian, R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev., 11: 1974-1986, 1997.
17. Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., and Lane, D. P. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene, 19: 2312-2323, 2000.
18. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 275: 8945-8951, 2000.
19. Geyer, R. K., Yu, Z. K., and Maki, C. G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol., 2: 569-573, 2000.
20. Honda, R., Tanaka, H., and Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumour suppressor p53. FEBS Lett., 420: 25-27, 1997.
21. Honda, R. and Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene, 19: 1473-1476, 2000.
22. Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P. A., Copeland, R. A., and Auger, K. R. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem., 276: 31357-31367, 2001.
23. Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P., and Hay, R. T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol., 20: 8458-8467, 2000.
24. Buschmann, T., Lerner, D., Lee, C-G., and Ronai, Z. The Mdm2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9. J. Biol. Chem., 276: 40389-40395, 2001.
25. Ashcroft, M., Taya, Y., and Vousden, K. H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol., 20: 3224-3233, 2000.
26. Appella, E. and Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268: 2764-2772, 2001.
27. Balint, E. and Vousden, K. H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer, 85: 1813-1823, 2001.
28. Gill, G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev., 13: 108-113, 2003.
29. Miyauchi, Y., Yogosawa, S., Honda, R., Nishida, T., and Yasuda, H. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J. Biol. Chem., 277: 50131-50136, 2002.
30. Xirodimas, D. P., Chisholm, J., Desterro, J. M. S., Lane, D. P., and Hay, R. T. p14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett., 528: 207-211, 2002.
31. Henning, W., Rohaly, G., Kolzau, T., Knippschild, U., Maacke, H., and Deppert, W. MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J. Virol., 71: 7609-7618, 1997.
32. Hay, T. J. and Meek, D. W. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett., 478: 183-186, 2000.
33. Mayo, L. D. and Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA, 98: 11598-11603, 2001.
34. Mayo, L. D., Turchi, J. J., and Berberich, S. J. Mdm2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res., 57: 5013-5016, 1997.
35. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E., and Oren, M. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev., 15: 1067-1077, 2001.
36. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA, 96: 14973-14977, 2000.
37. McCoy, M. A., Gesell, J. J., Senior, M. M., and Wyss, D. F. Flexible lid to the p53 binding domain of human Mdm2: implications for p53 regulation. Proc. Natl. Acad. Sci. USA, 100: 1645-1648, 2003.
38. de Toledo, S. M., Azzam, E. I., Dahlberg, W. K., Gooding, T. B., and Little, J. B. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene, 19: 6185-6193, 2000.
39. Wang, J. Y. Regulation of cell death by the Ab1 tyrosine kinase. Oncogene, 19: 5643-5650, 2000.
40. Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshawboris, A., Kastan, M. B., and Wang, J. Y. J. Ataxia telangiectasia mutant protein activates c-Ab1 tyrosine kinase in response to ionizing radiation. Nature, 387: 450-451, 1997.
41. Shafman, T., Khanna, K. K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D., and Lavin, M. Interaction between ATM protein and c-Ab1 in response to DNA damage. Nature, 387: 520-523, 1997.
42. White, E. and Prives, C. DNA damage enables p73. Nature, 399: 734-737, 1999.
43. Sionov, R. V., Moallem, E., Berger, M., Kazaz, A., Gerlitz, O., Ben-Neriah, Y., Oren, M., and Haupt, Y. c-Ab1 neutralizes the inhibitory effect of Mdm2 on p53. J. Biol. Chem., 274: 8371-8374, 1999.
44. Sionov, R. V., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., and Haupt, Y. c-Ab1 regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol. Cell. Biol., 21: 5869-5878, 2001.
45. Goldberg, Z., Sionov, R. V., Berger, M., Zwang, Y., Perets, R., Van Etten, R. A., Oren, M., Taya, Y., and Haupt, Y. Tyrosine phosphorylation of Mdm2 by c-Ab1: implications for p53 regulation. EMBO J., 21: 3715-3727, 2002.
46. Lawlor, M. A. and Alessi, D. R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J. Cell Sci., 114: 2903-2910, 2001.
47. Vanhaesebroeck, B. and Alessi, D. R. The P13K-PDK1 connection: more than just a road to PKB. Biochem. J., 346: 561-576, 2000.
48. Ashcroft, M., Ludwig, R. L., Woods, D. B., Copeland, T. D., Weber, H. O., MacRae, E. J., and Vousden, K. H. Phosphorylation of HDM2 by Akt. Oncogene, 21: 1955-1962, 2002.
49. Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y., and Oren, M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene, 21: 1299-1303, 2002.
50. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., and Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem., 277: 5484-5489, 2002.
51. Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., and Gotoh, Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem., 277: 21843-21850, 2002.
52. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol., 3: 973-982, 2001.
53. Zhou, B. B. and Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature, 408: 433-439, 2000.
54. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bosc, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275: 1943-1947, 1997.
55. Maier, D., Zhang, Z., Taylor, E., Hamou, M. F., Gratzl, O., Van Meir, E. G., Scott, R. J., and Merlo, A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene, 16: 1333-1335, 1998.
56. Mayo, L. D. and Donner, D. B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci., 27: 462-467, 2002.
57. Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., and Gu, W. Pare: a cytoplasmic anchor for p53. Cell, 112: 29-40, 2003.
58. Lin, H-K., Wang, L., Hu, Y-C., Altuwaijri, S., and Chang, C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J., 21: 4037-4048, 2002.
59. Zhang, T. and Prives, C. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem., 276: 29702-29710, 2001.
60. Argentini, M., Barboule, N., and Wasylyk, B. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene, 20: 1267-1275, 2001.
61. Zhu, Q., Yao, J., Wani, G., Wani, M. A., and Wani, A. A. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J. Biol. Chem., 276: 29695-29701, 2001.
62. Blattner, C., Hay, T., Meek, D. W., and Lane, D. P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol., 22: 6170-6182, 2002.
63. Guerra, B., Gotz, C., Wagner, P., Montenarh, M., and Issinger, O-G. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalysed MDM2 phosphorylation. Oncogene, 14: 2683-2688, 1997.
64. Gotz, C., Kartarius, S., Scholtes, P., Nastainczyk, W., and Montenarh, M. Identification of a CK2 phosphorylation site in mdm2. Eur. J. Biochem., 266: 493-501, 1999.
65. Hjerrild, M., Milne, D., Dumaz, N., Hay, T., Issinger, O. G., and Meek, D. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem. J., 355: 347-356, 2001.
66. Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., and Lu, H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell, 7: 283-292, 2001.
67. Hupp, T. R., Mcek, D. W., Midgley, C. A., and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
68. Waterman, M. J. F., Stavridi, E. S., Waterman, J. L. F., and Halazonetis, T. D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet., 19: 175-178, 1998.
69. Okamoto, K. and Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 13: 4816-4822, 1994.
70. Chen, X. Cyclin G: regulator of the p53 network. Dev. Cell, 2: 518-519, 2002.
71. Okamoto, K., Kamibayashi, C., Serrano, M., Prives, C., Mumby, M., and Beach, D. p53-dependent association between cyclin G and the B′ subunit of protein phosphatase 2A. Mol. Cell. Biol., 16: 6593-6602, 1996.
72. Kimura, S. H. and Nojima, H. Cyclin G1 associates with MDM2 and regulates accumulation and degradation of P53 protein. Genes Cells, 7: 869-880, 2002.
73. Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., and Prives, C. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol. Cell, 9: 761-771, 2002.